Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma
NCT00002781 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2013-09-17
Summary
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue.
PURPOSE: Phase I trial to study the effectiveness of boron neuron capture therapy in treating patients with stage III melanoma.
Conditions
- Melanoma (Skin)
Interventions
- DRUG
-
boronophenylalanine-fructose complex
Sponsors & Collaborators
-
Beth Israel Deaconess Medical Center
lead OTHER
Principal Investigators
-
Paul M. Busse, MD, PhD · Beth Israel Deaconess Medical Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1996-04-30
Countries
- United States
Study Locations
More Related Trials
-
PS-341 in Treating Patients With Metastatic Malignant Melanoma
NCT00024011 ·Status: COMPLETED ·Phase: PHASE2
-
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00007969 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
NCT01462773 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
NCT01308762 ·Status: COMPLETED ·Phase: PHASE1
-
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
NCT04904120 ·Status: COMPLETED ·Phase: PHASE1
-
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
NCT00027742 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
NCT01316692 ·Status: TERMINATED ·Phase: PHASE2
-
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
NCT02581930 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
NCT02990416 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors
NCT00278018 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
NCT01676779 ·Status: COMPLETED ·Phase: PHASE2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
NCT02965716 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
NCT05732805 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
NCT00243061 ·Status: COMPLETED ·Phase: PHASE2
-
Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging
NCT02056522 ·Status: COMPLETED
-
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
NCT00314106 ·Status: COMPLETED ·Phase: PHASE2
-
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
NCT00002763 ·Status: UNKNOWN ·Phase: PHASE3
-
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
NCT03873818 ·Status: COMPLETED ·Phase: PHASE2
-
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
NCT00289627 ·Status: COMPLETED ·Phase: PHASE2
-
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
NCT01078961 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II, 2nd Line Melanoma - RAND Monotherapy
NCT00612664 ·Status: COMPLETED ·Phase: PHASE2
-
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
NCT03727789 ·Status: TERMINATED ·Phase: PHASE1
-
BMS-247550 in Treating Patients With Stage IV Melanoma
NCT00036764 ·Status: COMPLETED ·Phase: PHASE2